FDA Orange Book
Is there a generic for Symbravo?
Symbravo contains meloxicam and rizatriptan benzoate. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Symbravo (meloxicam and rizatriptan benzoate). The Orange Book shows its last listed patent expires March 10, 2045 and its last listed exclusivity ends January 30, 2028.
Run it in Rivvi
Map Symbravo and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Symbravo products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 20MG;EQ 10MG BASE | Marketed (Rx) | None | 0 | None |
NDA 215431, held by AXSOME THERAPEUTICS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Symbravo patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 10702535 | April 11, 2036 | Method of use | U-4136 | 215431 |
| 10702602 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11013806 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10722583 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10987358 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10729696 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10688102 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11865117 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10729697 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11617755 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10729773 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10517950 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11426414 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 9821075 | April 11, 2036 | Drug product | U-1719 | 215431 |
| 10029010 | April 11, 2036 | Method of use | U-4133 | 215431 |
| 10137131 | April 11, 2036 | Drug product | U-1719 | 215431 |
| 10195278 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10695429 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10265324 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11369684 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10695430 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10363312 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10688185 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10653777 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10583144 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11331323 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10561664 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10537642 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10369224 | April 11, 2036 | Method of use | U-4134 | 215431 |
| 10532101 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11285213 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10426839 | April 11, 2036 | Method of use | U-4135 | 215431 |
| 10471014 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11219626 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10471069 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10512692 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11207328 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10512693 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11135295 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11045549 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11020483 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11826370 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10940153 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11602563 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11806354 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11510927 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10933137 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11504429 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11471464 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10933136 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11801250 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10799588 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10780165 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10821181 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11759522 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10758618 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 10918722 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11738085 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11013805 | April 11, 2036 | Method of use | U-1719 | 215431 |
| 11712441 | April 11, 2036 | Method of use | U-1719 | 215431 |
Showing 60 of 96 listed patents.
Symbravo exclusivity
| Code | Meaning | Expires | NDA |
|---|---|---|---|
| NP | New product | January 30, 2028 | 215431 |
Symbravo NDC codes
Questions
Is there a generic for Symbravo?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Symbravo (meloxicam and rizatriptan benzoate). The Orange Book shows its last listed patent expires March 10, 2045 and its last listed exclusivity ends January 30, 2028.
What is the generic name for Symbravo?
The active ingredient in Symbravo is meloxicam and rizatriptan benzoate, per the FDA Orange Book.
When does the Symbravo patent expire?
The last patent listed for Symbravo in the Orange Book expires March 10, 2045. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.